The Peptide CommonsEst. May 2024
Independent. We sell nothing and are affiliated with no manufacturer or pharmacy. Every moderation action is logged in public
Tags · Compound

semaglutide

GLP-1 receptor agonist; the compound with the largest published human dataset in this class.

80 topics 17 solved Synonyms: sema Group: Compound

Related in this group: tirzepatide · retatrutide · cagrilintide · cagrisema · liraglutide · dulaglutide · exenatide · orforglipron · oral semaglutide · survodutide · mazdutide · amylin analogues

80 topics · page 3 of 3

TopicParticipantsRepliesViewsActivity
Second pass at: Semaglutide and alcohol: what is actually documented
Second pass at: Semaglutide and alcohol: what is actually documented Writing it up because I had to work it out twice and would rather nobody else did. I have seen STEP 1 ( N Engl J Med , 2021) cited in…
IBDNOFID+15 19 4.4k 13mo
[2026 update] Dose numbers across compounds are not on the same scale
On the subject in the title: Dose numbers across compounds are not on the same scale Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I am asking…
KVBVHDITNL+14 18 1.2k 13mo
Half-life, steady state, and accumulation worked through
Half-life, steady state, and accumulation worked through Writing it up because I had to work it out twice and would rather nobody else did. Working through the identity arithmetic and I would like it checked.…
OVJSRPTS+115 130 44k 13mo
Albumin binding and how it produces a long half-life
Albumin binding and how it produces a long half-life — setting out what I have, and where I think it stops being reliable. I would like to understand what this number means before I repeat it anywhere. A…
SDDMTBBTAM+38 44 6.6k 14mo
Reaching a dose and staying there for a year: a longitudinal note
Reaching a dose and staying there for a year: a longitudinal note Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still have a…
RFNRHC 2 763 15mo
Why appetite effects are mostly central
Why appetite effects are mostly central I have a specific reason for asking rather than idle curiosity, and the context is below. Posting the method first, because I know what the first three replies will…
EKHFSB 2 56k 16mo
Biased agonism: a real phenomenon, an over-used explanation
Posting this under the heading it deserves: Biased agonism: a real phenomenon, an over-used explanation Everything below is what sits behind that. A documentation question rather than an analytical one. I…
HASLFRGTSL+130 135 23k 16mo
Titrating on tolerability rather than on the calendar — the long version
Titrating on tolerability rather than on the calendar — the long version Writing it up because I had to work it out twice and would rather nobody else did. Reporting something rather than asking about it, in…
MDOARM 2 7.7k 17mo
Second pass at: Albumin binding and how it produces a long half-life
Posting this under the heading it deserves: Second pass at: Albumin binding and how it produces a long half-life Everything below is what sits behind that. I would like to understand what this number means…
BRIJVPYR+7 11 31k 17mo
Semaglutide in people without diabetes: what the evidence base looks like
Semaglutide in people without diabetes: what the evidence base looks like Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016).…
GCSDNVMHN+2 6 18k 17mo
Revisiting: Holding a dose indefinitely: is there a documented downside?
The question in the title: Revisiting: Holding a dose indefinitely: is there a documented downside? I will give what I have already checked below so nobody repeats it. A question about technique rather than…
MVBVPKCC+26 30 4.5k 18mo
Follow-up: Where the four-week escalation interval comes from, and what it is not
Where the four-week escalation interval comes from, and what it is not Writing it up because I had to work it out twice and would rather nobody else did. I have read the maintained page on this and I still…
TNOBJEPPMV+131 147 47k 18mo
Follow-up: Semaglutide versus liraglutide head to head: reading STEP 8 carefully
Semaglutide versus liraglutide head to head: reading STEP 8 carefully — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim…
DYKBFHKVM+1 5 11k 20mo
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold?
Tracking semaglutide's approved indications across jurisdictions, dated — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N…
NSZSKRSIUC+58 62 49k 20mo
Glucagon receptor agonism in a weight-loss compound
On the subject in the title: Glucagon receptor agonism in a weight-loss compound Working notes rather than a conclusion. Posting the method first, because I know what the first three replies will otherwise…
OBLMJM 2 5.1k 20mo
Time to steady state after a dose increase
On the subject in the title: Time to steady state after a dose increase Working notes rather than a conclusion. A documentation question rather than an analytical one. I have a certificate in front of me that…
LCKJSLKC+151 163 9.7k 21mo
The C-cell question: rodent findings and their human context — what changed since
The C-cell question: rodent findings and their human context — what changed since — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support…
TKJEPPSDPN+61 65 1.3k 22mo
The most common factual error about semaglutide on the internet
On the subject in the title: The most common factual error about semaglutide on the internet Working notes rather than a conclusion. Session topic: STEP 2 ( Lancet , 2021). Please read it before posting; the…
HDLVFN 2 49k 2y
Where the four-week escalation interval comes from, and what it is not
On the subject in the title: Where the four-week escalation interval comes from, and what it is not Working notes rather than a conclusion. I have read the maintained page on this and I still have a gap, so I…
CCNWVNRW+56 60 21k 2y
Splitting a weekly dose in two: the pharmacokinetic argument against — the long version
Posting this under the heading it deserves: Splitting a weekly dose in two: the pharmacokinetic argument against — the long version Everything below is what sits behind that. Reporting something rather than…
JSSSIBSBSO+138 148 1.8k 2y